Home Journals Articles Updates About
CN
image
收藏切换
Research status on clinical application of targeted drugs in hepatocellular carcinoma
收藏切换
PDF
Bo-zeng QIU1, 2, Jun-li LIN1, Jian-min GUO1, Song-qiang XIE2, Wei YANG1
Chinese Journal of Clinical Pharmacology | 2025, 41(11) : 1619 - 1623
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2025, 41(11): 1619-1623
• Review •
Research status on clinical application of targeted drugs in hepatocellular carcinoma
Full
Bo-zeng QIU1, 2, Jun-li LIN1, Jian-min GUO1, Song-qiang XIE2, Wei YANG1
Affiliations
  • 1.Guangzhou Bay Area Institute of Biomedicine, Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd., Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, Guangdong Engineering Research Center for Innovative Drug Evaluation and Research, Conghua Engineering Technology Research Center of Drugs Pharmacokinetics and Toxicokinetics, Guangzhou 510990, Guangdong Province, China
  • 2.School of Pharmacy, Henan University, Kaifeng 475000, Henan Province, China
Published: 2025-06-17 doi: 10.13699/j.cnki.1001-6821.2025.11.021
Outline
收藏切换

Hepatocellular carcinoma (HCC) is the most common type of primary hepatocellular carcinoma, and advanced HCC is severe, difficult to treat, and has a poor prognosis. Since most patients have already lost the chance of surgery at the time of diagnosis, systemic drug therapy has become the main therapeutic tool. Currently, targeted therapeutic agents for advanced HCC are mainly divided into two categories: Tyrosine kinase inhibitors and vascular endothelial growth factor inhibitors. Approved tyrosine kinase inhibitors include sorafenib, lenvatinib, donafenib, regorafenib, cabozantinib and apatinib, etc. Vascular endothelial growth factor inhibitors include ramucirumab and bevacizumab. In recent years, the combination of targeted therapeutics and immune checkpoint inhibitors has effectively prolonged the overall survival of patients in several clinical trials, and this treatment model has become an important breakthrough in the current systemic treatment of advanced HCC. This article provides a brief introduction to the clinical application of targeted therapeutics for HCC.

targeted therapy drug  /  tyrosine kinase inhibitor  /  vascular endothelial growth factor inhibitor  /  hepatocellular carcinoma
Bo-zeng QIU, Jun-li LIN, Jian-min GUO, Song-qiang XIE, Wei YANG. Research status on clinical application of targeted drugs in hepatocellular carcinoma[J]. Chinese Journal of Clinical Pharmacology, 2025 , 41 (11) : 1619 -1623 . DOI: 10.13699/j.cnki.1001-6821.2025.11.021
Appendix
Less
Year 2025 volume 41 Issue 11
PDF
0
0
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2025.11.021
  • Receive Date：2024-12-26
  • Online Date：2026-08-04
  • Published：2025-06-17
Article Data
Affiliations
History
  • Received：2024-12-26
Funding
Affiliations
    1.Guangzhou Bay Area Institute of Biomedicine, Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd., Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, Guangdong Engineering Research Center for Innovative Drug Evaluation and Research, Conghua Engineering Technology Research Center of Drugs Pharmacokinetics and Toxicokinetics, Guangzhou 510990, Guangdong Province, China
    2.School of Pharmacy, Henan University, Kaifeng 475000, Henan Province, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2025.11.021
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House